New agent proves its value in breast scintigraphy scans
Breast scintigraphy with technetium-99m NC100692 is safe and effective and could be used to monitor cancer treatment response, according to a study published in the September issue of the Journal of Nuclear Medicine
Breast scintigraphy with technetium-99m NC100692 is safe and effective and could be used to monitor cancer treatment response, according to a study published in the September issue of the Journal of Nuclear Medicine.
Researchers at the Karolinska Institute of Stockholm and the Norwegian Radiumhospital in Oslo tested Tc-99m NC100692 in a study of 16 patients with suspicious mammograms and four patients with benign breast lesions 6 mm or larger. Imaging with the new agent detected 19 of 22 malignant lesions.
No serious adverse events were encountered with the new agent, though mild side effects occurred in five patients. Tc-99m sestamibi has been used in the past to support mammography, but its sensitivity never went beyond 50% for lesions smaller than 12 mm. Tc-99m NC100692 showed 100% sensitivity for lesions 10 mm or larger.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
